The stock of Emergent Biosolutions Inc (NYSE:EBS) gapped up by $0.25 today and has $46.35 target or 47.00% above today’s $31.53 share price. The 6 months technical chart setup indicates low risk for the $1.21 billion company. The gap was reported on Oct, 1 by Barchart.com. If the $46.35 price target is reached, the company will be worth $568.70M more.
Gaps up are useful for using as a support level and to some extent as a tradeable event. If investors already hold the stock and experience a price gap up, then its usually a good idea to hold the stock for a stronger up move. Back-tests of these patterns indicate that two-thirds of the times the stock performance improves after the gap. The area gaps close 89% of the time, the breakaway gaps, 2%, the continuation gaps 4% and the exhaustion gaps 61%. The stock increased 13.58% or $3.77 on September 30, hitting $31.53. About 1.40 million shares traded hands or 231.01% up from the average. Emergent Biosolutions Inc (NYSE:EBS) has declined 6.80% since February 29, 2016 and is downtrending. It has underperformed by 17.22% the S&P500.
Analysts await Emergent Biosolutions Inc (NYSE:EBS) to report earnings on November, 3. They expect $0.42 earnings per share, down 49.40% or $0.41 from last year’s $0.83 per share. EBS’s profit will be $16.12M for 18.77 P/E if the $0.42 EPS becomes a reality. After $-0.18 actual earnings per share reported by Emergent Biosolutions Inc for the previous quarter, Wall Street now forecasts -333.33% EPS growth.
Emergent Biosolutions Inc (NYSE:EBS) Ratings Coverage
Out of 3 analysts covering Emergent Biosolutions (NYSE:EBS), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Emergent Biosolutions has been the topic of 5 analyst reports since August 10, 2015 according to StockzIntelligence Inc. Singular Research maintained the shares of EBS in a report on Tuesday, June 28 with “Buy” rating. The firm earned “Hold” rating on Monday, August 10 by Zacks. On Friday, April 15 the stock rating was initiated by Chardan Capital Markets with “Buy”. Wells Fargo initiated the stock with “Outperform” rating in Friday, February 19 report. Singular Research initiated Emergent Biosolutions Inc (NYSE:EBS) on Monday, March 28 with “Buy” rating.
According to Zacks Investment Research, “EMERGENT BIOSULUTIONS INC. is a leading biopharmaceutical company dedicated to one simple mission – to protect life. EBS develops, manufactures and commercializes vaccines and therapeutics that assist the body’s immune system to prevent or treat disease. Their products target infectious diseases and other medical conditions that have resulted in significant unmet or underserved public health needs. Their marketed product, BioThraxÂ® (Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax infection.”
Insitutional Activity: The institutional sentiment increased to 1.56 in Q2 2016. Its up 0.33, from 1.23 in 2016Q1. The ratio is positive, as 25 funds sold all Emergent Biosolutions Inc shares owned while 55 reduced positions. 35 funds bought stakes while 90 increased positions. They now own 35.17 million shares or 5.50% more from 33.34 million shares in 2016Q1.
State Of Tennessee Treasury Department accumulated 0% or 24,170 shares. Mycio Wealth Prns Limited Company has 0% invested in the company for 500 shares. Lord Abbett And Com Limited Com owns 86,120 shares or 0.01% of their US portfolio. Moreover, Tradewinds Global Lc has 0.02% invested in Emergent Biosolutions Inc (NYSE:EBS) for 8,360 shares. Bnp Paribas Arbitrage Sa holds 0% or 9,806 shares in its portfolio. Kistler accumulated 0% or 9 shares. Putnam Investments Lc accumulated 201,490 shares or 0.01% of the stock. Mesirow Invest Management holds 0.9% of its portfolio in Emergent Biosolutions Inc (NYSE:EBS) for 548,999 shares. The Delaware-based Blackrock Limited Liability Corp has invested 0% in Emergent Biosolutions Inc (NYSE:EBS). Raymond James & Assocs owns 8,456 shares or 0% of their US portfolio. Northern Tru Corp owns 534,798 shares or 0% of their US portfolio. Geode Lc, a Massachusetts-based fund reported 248,391 shares. Us Bank De last reported 32,578 shares in the company. Sawgrass Asset Mgmt Limited Liability Com has invested 0.03% of its portfolio in Emergent Biosolutions Inc (NYSE:EBS). Secor Cap Advsr Lp owns 53,891 shares or 0.18% of their US portfolio.
Insider Transactions: Since April 1, 2016, the stock had 0 insider purchases, and 15 insider sales for $14.83 million net activity. The insider Kramer Robert sold 43,572 shares worth $1.55 million. The insider Abdun-Nabi Daniel sold $380,494. 4,700 Emergent Biosolutions Inc (NYSE:EBS) shares with value of $207,364 were sold by JOULWAN GEORGE A. 50,000 Emergent Biosolutions Inc (NYSE:EBS) shares with value of $1.95 million were sold by El-Hibri Fuad. Hauer Jerome M also sold $129,183 worth of Emergent Biosolutions Inc (NYSE:EBS) on Thursday, May 19. SULLIVAN LOUIS W had sold 47,631 shares worth $1.87 million. $1.18 million worth of Emergent Biosolutions Inc (NYSE:EBS) shares were sold by Harsanyi Zsolt.
More notable recent Emergent Biosolutions Inc (NYSE:EBS) news were published by: Fool.com which released: “Why Emergent Biosolutions Inc Surged Higher Today” on September 30, 2016, also Forbes.com with their article: “Emergent BioSolutions Is Oversold” published on June 27, 2016, Fool.com published: “Why Emergent BioSolutions Inc. Procured a Lower Price Today” on June 22, 2016. More interesting news about Emergent Biosolutions Inc (NYSE:EBS) were released by: Benzinga.com and their article: “Emergent Biosolutions Shares Up 13% on Heavy Volume; Co. Earlier Offered …” published on September 30, 2016 as well as Fool.com‘s news article titled: “Emergent BioSolutions Inc. Asks for Patience” with publication date: August 11, 2016.
EBS Company Profile
Emergent BioSolutions Inc., incorporated on December 19, 2003, is a biopharmaceutical firm that offers specialized products to healthcare providers and governments to address medical needs and emerging health threats. The Firm develops, makes and delivers a portfolio of medical countermeasures primarily for government agencies in the areas of biological and chemical threats and emerging infectious diseases (EID). It also develops and commercializes therapeutics, and other specialty products for hospitals and clinics in the areas of hematology/oncology, transplantation, infectious diseases and autoimmune disorders. The Company’s two operating divisions include Biodefense and Biosciences.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.